AstraZeneca, a multinational pharmaceutical and biotechnology company, has announced plans to open a new R&D site in Cambridge, Massachusetts. The new facility, located in Kendall Square, will also operate as a headquarters for AstraZeneca’s subsidiary company, Alexion. It is expected to commence operations in 2026 and will consolidate 1,500 commercial, R&D and corporate staff into a single location.
Pascal Soriot, CEO at AstraZeneca, commented in a company press release: “Kendall Square, Cambridge, is at the heart of the life sciences and innovation hub of the greater Boston area, and our new site will put us right at the centre of this space. The move will provide access to some of the most innovative partners in academia and biotech, offering opportunities to accelerate our growth and collaborate with like-minded organisations as we continue to push the boundaries of science to deliver advances for patients.”
AstraZeneca was founded in 1999 and is headquartered in Cambridge, UK. The company focuses on three main therapy areas – oncology, cardiovascular and metabolic disease – and operates in 100 countries worldwide.
